<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666807</url>
  </required_header>
  <id_info>
    <org_study_id>TehranUMS</org_study_id>
    <nct_id>NCT02666807</nct_id>
  </id_info>
  <brief_title>Effects of Ginger Supplementation on NF-KB in Peripheral Blood Mononuclear Cells in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effects of Oral Ginger Supplementation on NF-KB (Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells) in Peripheral Blood Mononuclear Cells (PBMC) and Glycemic and Lipid Profiles in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of ginger on NF-KB level in Peripheral Blood Mononuclear
      Cells in type 2 diabetic patients. Half of patients will receive ginger, while the other half
      will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ginger is a plant with lots of phytochemicals which have antioxidant effects. It reduces the
      NF-KB levels in the cells because of its antioxidant effects. It can reduces insulin
      resistance as a result of NF-KB reduction in diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in NF-KB at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in FBS (mg/dl) at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>FBS (Fasting Blood sugar) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HDL-C (mg/dl) at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>HDL-C (High Density Lipoprotein) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in LDL-C (mg/dl) at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>LDL-C (Low Density Lipoprotein) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total-C (mg/dl) at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Total-C (Total Cholesterol) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in TG (mg/dl) at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>TG (Triacylglycerol) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hb A1C at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Hb A1C (Glycated hemoglobin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in insulin (ÂµlU/ml) at 10 weeks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ginger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ginger (Zingiber officinale Roscoe) 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks Placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ginger</intervention_name>
    <description>Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks</description>
    <arm_group_label>Ginger</arm_group_label>
    <other_name>Zingiber officinale Roscoe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>wheat flour capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 of diabetes diagnosed for 1 to 10 years

          -  age 30-60 years

          -  BMI = 18.5-35 kg/m*m

          -  treatment with Metformin or Glibenclamide

        Exclusion Criteria:

          -  Treatment with insulin

          -  Weight loss more than 10% in 6 months

          -  Treatment with TZDs (thiazolidinediones)

          -  Pregnancy and breast feeding

          -  Smoking and alcohol consumption

          -  Multivitamin-mineral and polyphenols and omega-3 and 6 supplementation in the last 3
             months and during study

          -  Ginger supplementation and herbal medicines

          -  Anticoagulation consumption such as heparin and warfarin

          -  NSAIDs such as diclofenac and salicylate drugs such as aspirin, corticosteroids such
             as prednisone consumption during 1 month ago and during the study

          -  Infectious and inflammatory diseases such as rheumatoid arthritis

          -  Impaired hepatic, renal and gastrointestinal function

          -  Cancer

          -  Currently suffering from acute illness that needs medical treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Saedisomeolia, Prof.assoc</last_name>
    <role>Study Director</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Motahare Makhdoomiarzati, Msc student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <results_reference>
    <citation>Jung HW, Yoon CH, Park KM, Han HS, Park YK. Hexane fraction of Zingiberis Rhizoma Crudus extract inhibits the production of nitric oxide and proinflammatory cytokines in LPS-stimulated BV2 microglial cells via the NF-kappaB pathway. Food Chem Toxicol. 2009 Jun;47(6):1190-7. doi: 10.1016/j.fct.2009.02.012. Epub 2009 Feb 20.</citation>
    <PMID>19233241</PMID>
  </results_reference>
  <results_reference>
    <citation>Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008 Feb;46(2):409-20. Epub 2007 Sep 18. Review.</citation>
    <PMID>17950516</PMID>
  </results_reference>
  <results_reference>
    <citation>Li XH, McGrath KC, Tran VH, Li YM, Duke CC, Roufogalis BD, Heather AK. Attenuation of Proinflammatory Responses by S-[6]-Gingerol via Inhibition of ROS/NF-Kappa B/COX2 Activation in HuH7 Cells. Evid Based Complement Alternat Med. 2013;2013:146142. doi: 10.1155/2013/146142. Epub 2013 Jun 16.</citation>
    <PMID>23843863</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogawa Y, Yamaguchi K, Tanaka T, Morozumi M, Kitagawa R. [Evaluation of the enzymatic method using oxalate oxidase for urinary oxalate assay]. Hinyokika Kiyo. 1987 Dec;33(12):1951-4. Japanese.</citation>
    <PMID>3448918</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tehran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Niaz Mohammadzadeh Honarvar</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>NF-ÎºB</keyword>
  <keyword>Ginger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

